glp-1 87 kg journey Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia | Current Nutrition Reports GLP-1-based therapies for diabetes, obesity

g = 0.54 [0.90 to 0.18])

Rao, R., & Samak, G

Subdiaphragmatic vagotomy with pyloroplasty ameliorates the obesity caused by genetic deletion of the melanocortin 4 receptor in the mouse

Prevention starts with protein intake, resistance training, micronutrient support, hydration, and gradual weight loss when medically possible

The part of our brain that controls our body weight (hypothalamus) notices any weight loss as starvation and unconsciously works via hormonal signaling to increase hunger and food cravings and decrease calorie burn to get your weight (specifically fat) back to where it was prior to weight loss

Moreover, both neuroinflammation [83] and oxidative stress play a role in the pathogenesis of AD [82]